Modulation of HIV-1-Induced activation of plasmacytoid dendritic cells by 6-desfluoroquinolones

AIDS Research and Human Retroviruses

Volumn 30, Issue 4, 2014, Pages 345-354

  Royle, Caroline M ^a   Tsai, Ming Han ^a   Tabarrini, Oriana ^b   Massari, Serena ^b   Graham, David R ^c   Aquino, Veronica N ^c   Boasso, Adriano ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PERUGIA   (Italy)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 DESFLUOROQUINOLONE DERIVATIVE; B7 ANTIGEN; BIOLOGICAL MARKER; CD83 ANTIGEN; CHLOROQUINE; DYLIGHT 488; FLUORESCENT DYE; GAMMA INTERFERON; QUINOLONE DERIVATIVE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ACIDIFICATION; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; ENDOSOME; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IN VITRO STUDY; INTERFERON PRODUCTION; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; UPREGULATION;

ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUOROQUINOLONES; HIV-1; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; MEMBRANE GLYCOPROTEINS;

EID: 84898726805     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0154     Document Type: Article

References (35)

1. Steinman RM and Hemmi H: Dendritic cells: Translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006;311:17-58. (Pubitemid 47413194)
2. Takeuchi O and Akira S: Recognition of viruses by innate immunity. Immunol Rev 2007;220:214-224. (Pubitemid 350045565)
3. Barber GN: Host defense, viruses, and apoptosis. Cell Death Differ 2001;8(2):113-126.
4. Beignon AS, McKenna K, Skoberne M, et al.: Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005;115(11): 3265-3275. (Pubitemid 41567591)
5. Boasso A and Shearer GM: Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 2008;126(3):235-242. (Pubitemid 351221427)
6. Herbeuval JP, Hardy AW, Boasso A, et al.: Regulation of TNFrelated apoptosis-inducing ligand on primary CD4 + T cells by HIV-1: Role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2005;102(39):13974-13979. (Pubitemid 41377688)
7. Stary G, Klein I, Kohlhofer S, et al.: Plasmacytoid dendritic cells express TRAIL and induce CD4 + T-cell apoptosis in HIV-1 viremic patients. Blood 2009;114(18):3854-3863.
8. Boasso A, Hardy AW, Landay AL, et al.: PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: Restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin Immunol 2008;129(1):132-144.
9. Rodriguez B, Lederman MM, Jiang W, et al.: Interferon-Alpha differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection. AIDS 2006;20(10):1379-1389. (Pubitemid 43948244)
10. Boasso A, Hardy AW, Anderson SA, Dolan MJ, and Shearer GM: HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One 2008;3(8):e2961.
11. Li Q, Estes JD, Schlievert PM, et al.: Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009;458(7241): 1034-1038.
12. Bosinger SE, Li Q, Gordon SN, et al.: Global genomic analysis reveals rapid control of a robust innate response in SIVinfected sooty mangabeys. J Clin Invest 2009;119(12):3556-3572.
13. Jacquelin B, Mayau V, Targat B, et al.: Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009; 119(12):3544-3555.
14. Boasso A, Royle CM, Doumazos S, et al.: Overactivation of plasmacytoid dendritic cells inhibits antiviral T-cell responses: A model for HIV immunopathogenesis. Blood 2011;118(19):5152-5162.
15. Ahmed A and Daneshtalab M: Nonclassical biological activities of quinolone derivatives. J Pharm Pharm Sci 2012; 15(1):52-72.
16. Tabarrini O, Massari S, and Cecchetti V: 6-Desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors. Future Med Chem 2010;2(7):1161-1180.
17. Tabarrini O, Sabatini S, Massari S, Pieroni M, Franzblau SG, and Cecchetti V: 6-Hydrogen-8-methylquinolones active against replicating and non-replicating mycobacterium tuberculosis. Chem Biol Drug Des 2012;80(5):781-786.
18. Tsai WP, Nara PL, Kung HF, and Oroszlan S: Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses 1990;6(4):481-489.
19. Savarino A, Gennero L, Chen HC, et al.: Anti-HIV effects of chloroquine: Mechanisms of inhibition and spectrum of activity. AIDS 2001;15(17):2221-2229. (Pubitemid 34059828)
20. Martinson JA, Montoya CJ, Usuga X, Ronquillo R, Landay AL, and Desai SN: Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: Implication for T-cell activation. Antimicrob Agents Chemother 2010; 54(2):871-881.
21. Ma JP, Xia HJ, Zhang GH, Han JB, Zhang LG, and Zheng YT: Inhibitory effects of chloroquine on the activation of plasmacytoid dendritic cells in SIVmac239-infected Chinese rhesus macaques. Cell Mol Immunol 2012;9(5):410-416.
22. Piconi S, Parisotto S, Rizzardini G, et al.: Hydroxychloroquine drastically reduces immune activation in HIVinfected, ART-treated, immunological non-responders. Blood 2011; 118(12):3263-3272.
23. Murray SM, Down CM, Boulware DR, et al.: Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010;84(22):12082-12086.
24. Paton NI, Goodall RL, Dunn DT, et al.: Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: A randomized controlled trial. JAMA 2012;308(4):353-361.
25. Tabarrini O, Stevens M, Cecchetti V, et al.: Structure modifications of 6-Aminoquinolones with potent anti-HIV activity. J Med Chem 2004;47(22):5567- 5578. (Pubitemid 39382803)
26. Tabarrini O, Massari S, Daelemans D, et al.: Structure-Activity relationship study on anti-HIV 6-desfluoroquinolones. J Med Chem 2008;51(17):5454-5458.
27. Massari S, Daelemans D, Barreca ML, et al.: A 1,8-naphthyridone derivative targets the HIV-1 Tat-mediated transcription and potently inhibits the HIV-1 replication. J Med Chem 2010;53(2):641-648.
28. Rossio JL, Esser MT, Suryanarayana K, et al.: Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 1998;72(10): 7992-8001. (Pubitemid 28421792)
29. Cecchetti V, Parolin C, Moro S, et al.: 6-Aminoquinolones as new potential anti-HIV agents. J Med Chem 2000;43(20): 3799-3802.
30. Moir S, Chun TW, and Fauci AS: Pathogenic mechanisms of HIV disease. Annu Rev Pathol 2011;6:223-248.
31. Ellegard R, Shankar EM, and Larsson M: Targeting HIV-1 innate immune responses therapeutically. Curr Opin HIV AIDS 2011;6(5):435-443.
32. Pelchen-Matthews A, da Silva RP, Bijlmakers MJ, Signoret N, Gordon S, and Marsh M: Lack of p56lck expression correlates with CD4 endocytosis in primary lymphoid and myeloid cells. Eur J Immunol 1998;28(11):3639-3647. (Pubitemid 28510774)
33. Pitcher C, Honing S, Fingerhut A, Bowers K, and Marsh M: Cluster of differentiation antigen 4 (CD4) endocytosis and adaptor complex binding require activation of the CD4 endocytosis signal by serine phosphorylation. Mol Biol Cell 1999;10(3):677-691. (Pubitemid 29144631)
34. Stevens M, Balzarini J, Tabarrini O, et al.: Cell-dependent interference of a series of new 6-Aminoquinolone derivatives with viral (HIV/CMV) transactivation. J Antimicrob Chemother 2005;56(5):847-855. (Pubitemid 41631907)
35. Kader M, Smith AP, Guiducci C, et al.: Blocking TLR7-And TLR9-mediated IFN-Alpha production by plasmacytoid dendritic cells does not diminish immune activation in early SIV infection. PLoS Pathog 2013;9(7):e1003530.